ALG6-congenital disorder of glycosylation

1. Disease Information

1.1 Definition and Nosology

ALG6‑congenital disorder of glycosylation type Ic (ALG6‑CDG) is a monogenic disorder of N‑linked protein glycosylation belonging to the group of congenital disorders of glycosylation (CDG), a rapidly expanding family of inherited metabolic diseases caused by defects in the synthesis, processing, and attachment of asparagine‑linked oligosaccharides to glycoproteins.[5][12][16] CDG are traditionally divided into type I disorders, which affect assembly of the lipid‑linked oligosaccharide (LLO) and its transfer to nascent polypeptides, and type II disorders, which involve trimming and processing of protein‑bound glycans in the ER and Golgi.[5][12][16] ALG6‑CDG is classified as a CDG type I (historically CDG‑Ic) because the primary defect resides in an ER membrane glucosyltransferase that modifies the LLO before transfer; specifically, ALG6 adds the first glucose residue to Man(_9)GlcNAc(_2)‑PP‑dolichol, initiating formation of Glc(_3)Man(_9)GlcNAc(_2) required for efficient N‑glycosylation.[1][4][5][16][18] The disease manifests as a multisystem syndrome but is dominated by neurological features, including hypotonia, psychomotor retardation, seizures, and ataxia, with variable systemic involvement of the gastrointestinal tract, liver, coagulation system, endocrine glands, skeleton, and heart.[2][3][5][12][13][15][16]

Orphanet defines ALG6‑CDG as “a form of congenital disorders of N‑linked glycosylation characterized by feeding problems, mild‑to‑moderate neurologic involvement with hypotonia, poor head control, developmental delay, ataxia, strabismus, and seizures, ranging from febrile convulsions to epilepsy,” noting that retinal degeneration and intestinal or liver involvement may occur in a minority of patients.[2] This description is consistent with early case series in which eight patients showed mainly neurological presentation with developmental retardation, muscular hypotonia, and epilepsy, but lacked typical CDG‑Ia features such as cerebellar hypoplasia, abnormal fat distribution, and inverted nipples.[15][5][16] A larger Euroglycan registry‑based cohort of 41 individuals further elaborated the phenotype, emphasizing epilepsy, proximal muscle weakness, ataxia, behavioral anomalies, limb malformations, protein‑losing enteropathy, and variable coagulation and endocrine abnormalities.[3][8][12][13] Collectively, these observations support classification of ALG6‑CDG as a distinct nosological entity within the MONDO ontology under MONDO:0011291, and within SNOMED CT and Orphanet as a rare autosomal recessive metabolic disorder of glycoprotein biosynthesis.[2][11][16]

1.2 Key Identifiers and Ontological Mapping

ALG6‑CDG has been assigned several standardized identifiers across human disease ontologies and clinical coding systems. OMIM designates the phenotype entry “congenital disorder of glycosylation, type Ic” with MIM number 603147, linked to the ALG6 gene entry 604566 on chromosome 1p31.3.[1][16] Orphanet lists the disorder under ORPHA:79320, with synonyms including “CDG syndrome type Ic,” “CDG‑Ic,” “CDG1C,” “carbohydrate‑deficient glycoprotein syndrome type Ic,” and “glucosyltransferase 1 deficiency,” and notes a prevalence of less than (1/1{,}000{,}000).[2] The MONDO ontology maps ALG6‑CDG to MONDO:0011291, aligning it with OMIM and Orphanet entries and related knowledge bases.[11][16] SNOMED CT includes a concept for ALG6‑CDG or closely related CDG‑Ic phenotypes under code 709412006, which is also referenced in the OMIM gene entry for ALG6.[1][16]

In terms of International Classification of Diseases coding, CDG as a group are generally coded under ICD‑10 category E74 (“Other disorders of carbohydrate metabolism”), most often E74.8 (“Other specified disorders of carbohydrate metabolism”), and more specifically under ICD‑11 as 5C53 (“Congenital disorders of glycoprotein metabolism”), though ICD‑11 subcodes do not yet distinguish individual CDG subtypes such as ALG6‑CDG.[5][12][16] For indexing in biomedical literature and databases, the disease aligns with MeSH terms such as “Congenital Disorders of Glycosylation,” “Glycoproteins/metabolism,” and “Inborn Errors of Metabolism,” though MeSH does not provide a subtype‑specific heading for ALG6‑CDG.[5][12] Ontology suggestions for knowledge base integration include MONDO:0011291 for the disease entity, HP:0000007 (Autosomal recessive inheritance) for inheritance, and NCIT:C84509 for “Congenital Disorder of Glycosylation.”

The principal gene involved, ALG6, has the HGNC‑approved symbol ALG6 (HGNC:23157), NCBI Gene ID 29929, and is annotated in UniProt as dolichyl pyrophosphate Man(_9)GlcNAc(_2) α‑1,3‑glucosyltransferase (human ortholog of yeast Alg6).[1][4][17][18] Ontologically, ALG6 is linked to GO biological process term GO:0006487 (protein N‑linked glycosylation), GO cellular component terms GO:0005789 (endoplasmic reticulum membrane) and GO:0005783 (endoplasmic reticulum), and GO molecular function term GO:0000030 (mannosyltransferase activity), though its specific glucosyltransferase activity is better captured by more detailed annotations in UniProt and glycosylation pathway databases.[4][17][18]

For clarity, the principal identifiers and synonyms can be summarized in the following table:

1.3 Synonyms, Naming History, and Information Sources

ALG6‑CDG has undergone several nomenclatural changes reflecting evolving understanding of CDG nosology. Historically, early reports used the term “carbohydrate‑deficient glycoprotein syndrome” (CDGS) for the entire group of N‑glycosylation defects, and ALG6‑CDG was referred to as “carbohydrate‑deficient glycoprotein syndrome type Ic,” “CDGS type Ic,” or “type V” in some series.[5][6][15][16] As the CDG community standardized terminology, these conditions were reclassified as “congenital disorders of glycosylation,” with ALG6‑CDG designated CDG‑Ic according to the type I (assembly/transfer) vs type II (processing) scheme.[5][16] Orphanet and clinical genetics resources now most commonly use “ALG6‑CDG,” “ALG6‑congenital disorder of glycosylation,” or “ALG6‑related CDG” to emphasize the causal gene.[2][6][11]

Orphanet lists multiple synonyms including “CDG syndrome type Ic,” “CDG‑Ic,” “CDG1C,” “carbohydrate deficient glycoprotein syndrome type Ic,” “congenital disorder of glycosylation type 1c,” “congenital disorder of glycosylation type Ic,” and “glucosyltransferase 1 deficiency,” reflecting both historical naming and mechanistic description.[2] Patient‑oriented resources such as Myriad Genetics similarly refer to “congenital disorder of glycosylation, ALG6‑related” and provide lay explanations emphasizing ALG6’s role in adding sugar molecules to proteins and fats.[6] OMIM uses “congenital disorder of glycosylation, type Ic; CDG Ic; CDG1C” for the phenotype entry and “ALG6 α‑1,3‑glucosyltransferase” for the gene entry.[1][16]

The information base for ALG6‑CDG is derived primarily from aggregated disease‑level resources, including curated monogenic disease databases (OMIM, Orphanet, MONDO), systematic reviews of CDG cohorts, and multi‑center registries such as Euroglycan, rather than from large‑scale electronic health record (EHR) datasets.[2][3][5][9][12][13][15][16] The key clinical and biochemical characteristics were defined in early case series from specialized metabolic centers and subsequently expanded through registry‑based cohorts and systematic reviews, with relatively few population‑based epidemiological studies due to the rarity of the condition.[3][9][12][13][15] Thus, current disease knowledge primarily reflects human clinical case reports and series (e.g., PMIDs:10852543, 27287710) and expert reviews (e.g., Pediatric Research 2002; modern CDG review PMC6331365) rather than high‑throughput observational datasets.[5][12][15][3]

2. Etiology

2.1 Genetic Causal Factors

The primary and essentially sole causal factor for ALG6‑CDG is the presence of biallelic pathogenic germline variants in the ALG6 gene, leading to loss of function of its encoded α‑1,3‑glucosyltransferase and consequent disruption of ER N‑glycosylation.[1][4][15][16] OMIM explicitly states that congenital disorder of glycosylation type Ic “is caused by homozygous or compound heterozygous mutation in the ALG6 gene on chromosome 1p31,” consolidating evidence from multiple families in which affected individuals carry deleterious ALG6 variants segregating in an autosomal recessive pattern.[16] The ALG6 gene maps to cytogenetic location 1p31.3 and spans approximately 71 kb on GRCh38, with 15 exons encoding a multi‑pass transmembrane protein localized to the ER membrane.[1][4] Functional studies in patient fibroblasts and model organisms have demonstrated that ALG6 deficiency leads to accumulation of dolichyl pyrophosphate‑linked Man(_9)GlcNAc(_2) and reduced glucosylated LLO intermediates, confirming the mechanistic link between ALG6 variants and N‑glycosylation defects.[1][10][15][18]

In the landmark Annals of Neurology series of eight CDG‑Ic patients, all were homozygous for an Ala333Val (A333V) missense mutation in ALG6, providing early evidence of a recurrent pathogenic variant and establishing ALG6 as the causal gene.[15] OMIM and subsequent genetic analyses describe a multi‑allelic origin for CDG‑Ic, with at least 20 different ALG6 pathogenic variants identified, including missense, in‑frame deletions, and other sequence changes that reduce or abolish enzymatic function.[9][16] A larger cohort study by Imbach et al. confirmed that ALG6 mutations result in a dolichol pyrophosphate‑Man(_9)GlcNAc(_2) α‑1,3‑glucosyltransferase deficiency, leading to “accumulation of Man(_9)GlcNAc(_2) intermediates” and characteristic biochemical abnormalities in LLO profiles.[15][16] These human clinical and biochemical data, complemented by yeast and mammalian ortholog studies, firmly establish ALG6 variants as the proximate genetic cause of ALG6‑CDG.[1][10][15][17][18]

There is no evidence that somatic mutations or mosaicism in ALG6 contribute to ALG6‑CDG; all reported cases involve germline variants inherited in an autosomal recessive fashion, with parents typically heterozygous carriers who are clinically unaffected.[2][3][15][16] The absence of disease in heterozygous carriers is consistent with the recessive inheritance model and suggests that at least approximately 50% of normal ALG6 activity (from one functional allele) is sufficient to maintain ER N‑glycosylation above a clinical threshold.[2][16] Ontologically, ALG6‑CDG can therefore be described using HP:0000007 (Autosomal recessive inheritance) for the inheritance pattern, and the causal gene can be annotated as HGNC:23157 with OMIM:604566 and NCBI Gene:29929.[1][2][4][16]

2.2 Pathogenic Variant Spectrum and Genotype–Phenotype Relationships

The pathogenic variant spectrum of ALG6 in CDG‑Ic includes several recurrent missense and in‑frame deletion variants, as well as a broader set of individually rare alleles.[9][15][16] Early studies identified the c.998T>C transition, resulting in p.Ala333Val (A333V), as a predominant allele in European patients, with all eight individuals in the initial Annals of Neurology series being homozygous for this mutation and exhibiting the characteristic CDG‑Ic phenotype.[15] OMIM’s review of ALG6‑CDG refers to “multi‑allelic origin” and notes that A333V is common but not exclusive, with other variants contributing to disease in different families.[16]

The comprehensive epidemiological review by Piedade and colleagues assembled data on 101 reported ALG6‑CDG patients and identified at least 20 different pathogenic ALG6 variants.[9] They observed that approximately half of ALG6‑CDG patients carried the A333V missense variant in homozygosity, highlighting a strong founder or common allele effect in European populations.[9] Another frequent variant is the missense L453V (c.1357T>G), with an allelic frequency of (0.012) in certain populations, and the Y131H missense variant, occurring at a frequency of (0.021) in the general North American population.[9] Based on these allelic frequencies, the birth rate of homozygotes for Y131H was predicted to be (4.55\times10^{-4}), underscoring the potential for unrecognized ALG6‑CDG or partial phenotypes in specific populations.[9] The 2016 JIMD cohort of 41 ALG6‑CDG patients found that the most common pathogenic protein alterations were p.A333V and p.I299Del, but reported no clear genotype–phenotype correlation, with clinical severity and organ involvement varying widely among individuals carrying the same variant.[3][8]

The following table summarizes key pathogenic variants described in ALG6‑CDG, with approximate features based on available data:

Functional classification according to ACMG/AMP criteria in ClinVar and other variant databases generally categorizes A333V, I299del, and other recurrent ALG6 mutations as pathogenic or likely pathogenic, based on segregation with disease in multiple families, predicted deleterious effects on protein function, and supportive biochemical evidence of enzyme deficiency and LLO abnormalities.[1][9][15][16] However, detailed ClinVar data are not included in the provided search results, and variant‑level ACMG annotations may evolve as new evidence emerges. Most variants affect conserved residues within transmembrane segments or luminal loops critical for glucosyltransferase activity; missense changes and in‑frame deletions likely impair substrate binding, catalytic function, or ER localization, leading to partial or complete loss of function.[1][15][17][18]

Genotype–phenotype correlations have been difficult to establish. The JIMD series explicitly notes that “the most common pathogenic protein alterations were p.A333V and p.I299Del, without any clear genotype–phenotype correlation,” indicating that individuals with the same homozygous variant can present with a broad range of clinical severities, from relatively mild neurologic impairment to severe multisystem disease with early death.[3][8] Similarly, the early A333V‑homozygous cohort showed variable degrees of developmental delay, epilepsy, and systemic features.[15] This lack of correlation suggests that modifier genes, environmental factors, stochastic events, and possibly epigenetic or cell‑type‑specific regulatory mechanisms modulate the expression of ALG6‑CDG, although specific modifiers have not been conclusively identified.[3][9][12][15][16]

2.3 Non‑Genetic Causal and Risk Factors

No environmental, infectious, or toxic exposures have been reported as primary causes of ALG6‑CDG, and the disease is consistently recognized as a monogenic inborn error of metabolism due to germline ALG6 variants.[2][5][12][16] Unlike multifactorial metabolic disorders, there is no evidence that lifestyle factors such as diet, physical activity, or occupational exposures can cause ALG6‑CDG in the absence of pathogenic ALG6 alleles, although such factors may influence disease course or symptom severity.[2][6][12][13]

Risk factors for developing ALG6‑CDG are therefore primarily genetic and demographic. Consanguinity increases the risk that both parents carry the same rare ALG6 pathogenic allele, thereby elevating the probability of homozygous offspring; this is a general principle for recessive diseases and is supported by case reports of CDG‑Ic in consanguineous families, although specific consanguinity rates for ALG6‑CDG were not detailed in the provided excerpts.[12][15][16] Family history of CDG or unexplained developmental delay, hypotonia, and multisystem involvement is also a strong risk factor for having an undiagnosed ALG6‑CDG, particularly in populations where A333V or other founder variants are relatively frequent.[9][15][16] Population genetic data indicate that certain ALG6 variants (e.g., Y131H, L453V) have non‑negligible carrier frequencies in specific populations, implying that unrecognized carriers and potential future cases may exist.[9] Overall disease prevalence is estimated at less than (1/1{,}000{,}000), but carrier frequency for individual variants can be substantially higher.[2][9]

From an ontological perspective, relevant risk‑related terms include HP:0000007 (Autosomal recessive inheritance), and for population genetics, NCIT concepts such as “Carrier” and “Founder Mutation,” although specific NCIT codes are not detailed here. CHEBI ontology is less relevant for causal factors, as no exogenous chemicals are implicated in disease causation.

2.4 Protective Factors and Gene–Environment Interactions

Specific genetic protective factors or modifier alleles that reduce the risk or severity of ALG6‑CDG have not been identified. It is plausible that polymorphisms in other N‑glycosylation pathway genes or ER quality‑control components could modulate disease expression by partially compensating for ALG6 deficiency, but this remains speculative and untested in human cohorts.[10][12][15] For carriers, having one normal ALG6 allele is protective against disease development, reflecting the recessive inheritance pattern; however, this is a trivial protective effect tied to Mendelian genetics rather than to specific modifier genes.[2][16]

Environmental protective factors are similarly undefined. Optimized nutrition, aggressive infection prevention, and prompt management of protein‑losing enteropathy and coagulopathy may reduce morbidity and mortality, but they do not prevent disease onset in genetically affected individuals.[3][6][13] No specific dietary supplement (e.g., mannose or other sugars) has proven protective or curative in ALG6‑CDG, in contrast to MPI‑CDG (CDG‑Ib) where oral mannose supplementation can ameliorate symptoms by bypassing the enzymatic block.[5][12]

Gene–environment interactions in ALG6‑CDG mainly influence disease course rather than primary causation. For example, infections may precipitate decompensation, worsening seizures, and exacerbating protein‑losing enteropathy or coagulopathy, thereby unmasking or aggravating clinical manifestations in susceptible individuals.[3][13][15] Similarly, metabolic stress, surgery, or other systemic stressors can interact with the underlying glycosylation defect to trigger acute clinical crises. However, such interactions modulate severity and progression rather than determine whether the disease develops. Ontological terms that might capture these interactions include GO:0006950 (response to stress) and HP:0001945 (decompensation), although specific gene–environment interaction databases currently have limited entries for rare CDG.

3. Phenotypes

3.1 Overall Phenotypic Architecture

ALG6‑CDG displays a multisystem phenotype with mandatory neurological involvement and highly variable systemic manifestations impacting growth, gastrointestinal function, liver, coagulation, endocrine systems, skeleton, heart, kidneys, and eyes.[2][3][12][13][15][16] The Orphanet definition emphasizes feeding problems, mild‑to‑moderate neurologic involvement with hypotonia, poor head control, developmental delay, ataxia, strabismus, and seizures, with retinal degeneration and intestinal or liver involvement occurring in a minority of patients.[2] The 2016 JIMD cohort found hypotonia and developmental delay in all 41 ALG6‑CDG patients and documented high frequencies of epilepsy, ataxia, proximal muscle weakness, failure to thrive, behavioral and limb anomalies, and protein‑losing enteropathy, as well as less frequent coagulation anomalies and dysmorphic features.[3][8] The 2019 CDG review and the 2021 liver involvement review further summarized ALG6‑CDG as a type I CDG with neurological symptoms, occasional hepatopathy, coagulopathy, endocrine abnormalities, and skeletal dysplasia.[12][13]

Phenotypic heterogeneity is notable. In the early eight‑patient series, clinical presentation was mainly neurological, with developmental retardation, muscular hypotonia, and epilepsy, and with milder overall course and better neurological outcomes than CDG‑Ia.[15] In contrast, the JIMD series observed that eleven children died before age four due to protein‑losing enteropathy, sepsis, or seizures, highlighting that severe systemic complications can occur.[3][8] Facial dysmorphism was rare, but seven patients showed missing phalanges and brachydactyly, and cyclic behavioral changes with autistic features and depressive episodes were prominent complaints in many families.[3][8] In Orphanet’s synthesis, a minority of patients show intestinal manifestations such as protein‑losing enteropathy and liver involvement, reflecting variability in organ involvement.[2] These data underscore the importance of capturing phenotype attributes such as age of onset, severity, progression, and frequency in structured form using HPO and related ontologies.

3.2 Neurological and Neurodevelopmental Features

Neurological involvement is a defining and universal feature of ALG6‑CDG. Across published series, all patients have manifested early‑onset hypotonia and developmental delay, often recognized in infancy or early childhood.[2][3][8][12][15][16] The JIMD cohort explicitly states: “We found hypotonia and developmental delay in all ALG6‑CDG patients,” emphasizing the consistency of these core features across diverse genotypes and geographic backgrounds (PMID:27287710).[3][8] Hypotonia typically presents as generalized decreased muscle tone, poor head control, delayed motor milestones, and clumsiness, often accompanied by proximal muscle weakness and ataxia.[2][3][12] The Annals of Neurology series similarly noted “muscular hypotonia and epilepsy” as central clinical features.[15]

Global developmental delay and intellectual disability are common. Many children experience delayed acquisition of gross motor skills (sitting, standing, walking) and language, with ultimate cognitive outcomes ranging from mild to moderate intellectual disability to more severe impairment.[2][3][12][15][16] Walking may be delayed until late childhood, and some individuals may never achieve independent ambulation, ultimately requiring wheelchairs.[3][6][12] Myriad Genetics notes that “poor muscle tone, developmental delay, behavioral problems, and intellectual disability [occur] in almost all cases,” consistent with formal clinical series.[6][3][12] HPO terms relevant to these features include HP:0001290 (Generalized hypotonia), HP:0001263 (Global developmental delay), and HP:0001249 (Intellectual disability).

Epilepsy is another major neurologic manifestation. In the JIMD cohort, epilepsy was reported in a majority of ALG6‑CDG patients, with nine individuals developing intractable seizures, sometimes contributing to early mortality.[3][8] Seizure types varied, including febrile convulsions, generalized tonic–clonic seizures, and other forms; Orphanet notes that seizures can range “from febrile convulsions to epilepsy,” reflecting variability in severity.[2] The Annals of Neurology series reported epilepsy in most of the eight patients, and Myriad’s summary underscores seizures as a “common” feature.[6][15] HPO terms include HP:0001250 (Seizures) and HP:0002529 (Epilepsy).

Cerebellar and extrapyramidal signs such as ataxia, dysmetria, and dysarthria are also documented. The JIMD cohort highlights ataxia as a characteristic feature, often in association with proximal muscle weakness, contributing to gait instability and motor incoordination.[3][8] Reviews of CDG note that ALG6‑CDG patients can exhibit ataxia, dysmetria, and dysarthria, although cerebellar hypoplasia typical of PMM2‑CDG is generally absent, consistent with the milder neurologic profile.[5][12][15] HPO terms HP:0001251 (Ataxia), HP:0001264 (Dysmetria), and HP:0001260 (Dysarthria) capture these manifestations.

Behavioral and psychiatric features are particularly striking in ALG6‑CDG. The JIMD cohort reports that “cyclic behavioral change, with autistic features and depressive episodes, was one of the most significant complaints,” suggesting that behavioral dysregulation and neuropsychiatric symptoms are central to family burden (PMID:27287710).[3][8] Myriad Genetics similarly notes “autistic or behavioral problems” in many affected individuals.[6] These features may include social communication difficulties, stereotyped behaviors, mood lability, irritability, and depressive periods. HPO terms such as HP:0000729 (Autistic behavior), HP:0000716 (Aggressive behavior), and HP:0000713 (Depression) are relevant. Formal quantitative quality‑of‑life instruments (e.g., EQ‑5D or SF‑36) have not been systematically applied in ALG6‑CDG cohorts, but anecdotal reports and clinical impressions indicate substantial impact on daily functioning, schooling, social participation, and family dynamics.[3][6][12]

Visual neurologic manifestations also occur. Orphanet notes strabismus and seizures as part of the neurologic involvement.[2] The broader CDG review identifies strabismus, nystagmus, optic hypoplasia, retinal pigmentary changes, and alacrima among potential ophthalmologic features in ALG6‑CDG.[12] These likely reflect central and peripheral nervous system involvement in ocular motor control and retinal integrity. HPO terms include HP:0000508 (Strabismus), HP:0000554 (Nystagmus), HP:0000602 (Optic disc hypoplasia), and HP:0000559 (Retinal pigmentary changes). Overall, neurological features are early in onset (typically infancy), often progressive in the first years of life, and may stabilize in survivors, but seizures and behavioral issues can remain episodic or fluctuating throughout life.[3][6][12][15]

3.3 Musculoskeletal and Skeletal Features

ALG6‑CDG is associated with distinct limb anomalies and broader musculoskeletal involvement. The JIMD cohort reported that “seven patients showed missing phalanges and brachydactyly,” indicating a recognizable pattern of digital dysplasia characterized by shortened fingers and toes and absent distal phalanges.[3][8] Myriad Genetics describes skeletal abnormalities including “shortening of fingers and toes, limited joint extension, short arms, and scoliosis,” suggesting that limb shortening and joint contractures are part of the phenotype in a subset of cases.[6] The broader CDG review lists “osteopenia, kyphoscoliosis, dysmorphic features, skeletal dysplasia, short stature” among musculoskeletal findings in ALG6‑CDG, though precise frequencies are not specified.[12] HPO terms relevant here include HP:0001156 (Brachydactyly), HP:0009803 (Absent distal phalanges), HP:0001384 (Limited joint mobility), HP:0002048 (Short stature), HP:0002650 (Scoliosis), and HP:0000938 (Kyphosis).

Muscular involvement overlaps with neurologic hypotonia and proximal muscle weakness. The JIMD cohort specifically highlighted proximal muscle weakness as a common feature, contributing to difficulties with climbing stairs, rising from chairs, and maintaining posture.[3][8] Muscle involvement likely reflects both central motor pathway dysfunction and peripheral neuromuscular impairment. Electromyography and nerve conduction studies, where performed, have suggested peripheral neuropathy in some CDG‑I patients, although detailed data for ALG6‑CDG are sparse in the excerpts.[12] HPO terms HP:0003198 (Proximal muscle weakness) and HP:0003473 (Peripheral neuropathy) are applicable.

Bone health may also be affected, with reported osteopenia and increased risk of fractures in some CDG patients, though this is better documented in other CDG subtypes than in ALG6‑CDG.[12] Still, given shared mechanisms of impaired glycosylation of bone matrix proteins and endocrine regulators (e.g., IGF‑1), osteopenia is biologically plausible and consistent with skeletal dysplasia noted in review tables.[12][13] The combination of skeletal anomalies, joint limitations, and muscle weakness significantly affects mobility, posture, and activities of daily living, often necessitating orthopedic interventions, physiotherapy, and adaptive devices, with profound quality‑of‑life impact.[3][6][12]

3.4 Growth, Nutrition, and Gastrointestinal Phenotypes

Growth failure and gastrointestinal involvement are prominent systemic features of ALG6‑CDG. Orphanet notes feeding problems and “failure to thrive” as characteristic, with onset in infancy.[2] The JIMD cohort observed that “in the majority of cases, failure to thrive” occurred, often linked to poor oral intake, vomiting, diarrhea, and protein‑losing enteropathy.[3][8] Myriad Genetics emphasizes “poor growth” and notes that many affected individuals may require feeding tubes and specialized nutritional support.[6] HPO terms HP:0001508 (Failure to thrive), HP:0004399 (Feeding difficulties in infancy), and HP:0001999 (Vomiting) capture these manifestations.

Protein‑losing enteropathy (PLE) is a particularly severe gastrointestinal complication in ALG6‑CDG. The JIMD series reports that eleven children died before age four years “due to protein losing enteropathy (PLE), sepsis, or seizures,” highlighting PLE as a major cause of mortality.[3][8] PLE presents with edema, diarrhea, hypoalbuminemia, and often hypogammaglobulinemia, reflecting excessive loss of plasma proteins into the intestinal lumen.[3][12][13] The comprehensive CDG review lists “protein losing enteropathy, diarrhea, failure to thrive, gastroesophageal reflux disease (GERD)” under gastrointestinal involvement for ALG6‑CDG.[12] In the liver involvement review, ALG6‑CDG is grouped among CDG types where liver can be variably involved in a multisystem disease, with hypoalbuminemia and edema often reflecting both intestinal and hepatic contributions.[13] HPO terms include HP:0001733 (Protein‑losing enteropathy), HP:0002014 (Diarrhea), HP:0002020 (Gastroesophageal reflux), HP:0002620 (Edema), and HP:0003073 (Hypoalbuminemia).

Beyond PLE, hepatopathy is variably present. The liver involvement review identified ALG6‑CDG among 34 CDG types in which the liver can be involved in a multisystem disease with mandatory neurological symptoms.[13] Their table shows that, for ALG6‑CDG, liver involvement was noted, with decreased antithrombin (AT) (reflecting coagulopathy), but not necessarily elevated transaminases or advanced fibrosis in most cases.[13] In the summarized data, ALG6‑CDG had 89 patients studied, with “X” indicating liver involvement and neurologic involvement, and a specific notation for decreased antithrombin.[13] The broader CDG review notes that ALG6‑CDG can present with hepatopathy with transaminitis, edema and hypoalbuminemia, and low cholesterol, though these features are less pronounced than in some other CDG types.[12] HPO terms HP:0001397 (Hepatomegaly), HP:0002910 (Elevated hepatic transaminases), and HP:0002155 (Hypertransaminasemia) apply.

Gastrointestinal and hepatic manifestations significantly impair quality of life. Chronic diarrhea, abdominal discomfort, PLE‑related edema, and frequent hospitalizations for dehydration, infections, or nutritional support are common burdens.[3][6][12][13] Nutritional failure may require long‑term enteral feeding via nasogastric or gastrostomy tubes, specialized formulas, and careful dietary management, and PLE may necessitate immunoglobulin replacement and albumin infusions.[3][6][13] These interventions correspond to NCIT clinical‑intervention concepts such as “Enteral Nutrition” and “Parenteral Fluid Therapy,” underscoring the intensive supportive care often required.

3.5 Hematologic and Coagulation Abnormalities

ALG6‑CDG frequently involves coagulation system abnormalities, reflecting the reliance of multiple clotting factors and regulators on proper N‑glycosylation. In the JIMD cohort, coagulation anomalies were present in less than (50\%) of cases, and interestingly, occurred “without spontaneous bleedings,” indicating that laboratory abnormalities may be common but clinically asymptomatic in many patients.[3][8] The broader CDG review lists “coagulopathy and thrombosis (factor II, V, VII, VIII, IX, X, XI, antithrombin III, protein C, protein S deficiency)” under ALG6‑CDG, suggesting that multiple coagulation factor and natural anticoagulant levels can be reduced or dysfunctional due to hypoglycosylation.[12] The liver involvement review’s table indicates decreased antithrombin (“↓ AT”) in ALG6‑CDG, further supporting coagulopathy.[13]

These abnormalities can predispose to both bleeding and thrombosis, though clinical expression appears variable. Case reports across CDG types describe deep vein thrombosis, stroke, and other thrombotic events in association with coagulation factor imbalances, and the liver review mentions deep vein thrombosis and pubertal abnormalities as features in ALG6‑CDG, though the excerpt is truncated.[13] HPO terms such as HP:0001928 (Abnormality of coagulation), HP:0001892 (Thrombosis), and HP:0001893 (Bleeding tendency) are relevant. Ontologically, these features also tie to NCIT concepts like “Anticoagulation Therapy” for treatment and to LOINC and SNOMED CT codes for specific coagulation tests.

Hematologic changes may extend beyond coagulation to hypogammaglobulinemia and immune involvement, particularly when protein‑losing enteropathy leads to immunoglobulin loss. The CDG review notes “hypogammopathy” among ALG6‑CDG features, and the liver involvement review highlights immunodeficiency in some CDG types with liver disease.[12][13] In ALG6‑CDG, hypogammaglobulinemia may contribute to recurrent infections, which in turn exacerbate systemic decompensation and increase mortality risk.[3][13] However, immunodeficiency is not uniformly present and appears less prominent than in certain other CDG (e.g., COG complex defects).[13] HPO:0004313 (Hypogammaglobulinemia) captures this phenotype.

3.6 Endocrine and Metabolic Phenotypes

ALG6‑CDG affects the endocrine system, with documented abnormalities in thyroid function, growth hormone/IGF‑1 axis, gonadal function, and glucose metabolism, reflecting the importance of glycosylation for hormone production, receptor function, and signaling.[12][13][14][16] The 2019 CDG review notes “thyroid abnormalities, IGF1 deficiency, hypogonadotropic hypogonadism, hyperinsulinemic hypoglycemia” among endocrine findings in ALG6‑CDG.[12] Hypothyroidism may manifest as low thyroid hormone levels with elevated TSH, potentially contributing to growth failure and developmental delay, while IGF‑1 deficiency and growth hormone axis disruption may further impair linear growth.[12][13] HPO terms HP:0000820 (Hypothyroidism), HP:0000832 (Low serum IGF‑1), and HP:0000088 (Short stature) capture these features.

Pubertal development and gonadal function in ALG6‑CDG females have been the subject of specific case investigations. Miller et al. (2011) described an ALG6‑deficient woman who “completed puberty with normal gonadotropins and testosterone levels, no virilization, and regular menses,” contrasting with prior reports of CDG females who exhibited hypergonadotropic hypogonadism and absent secondary sexual characteristics (PMID:21151688).[14] They noted that abnormal protein glycosylation in CDG impacts the endocrine system, affecting growth, thyroid, adrenal function, glucose metabolism, and pubertal development.[14] In a previously described ALG6‑CDG female, elevated testosterone and signs of virilization were observed, and two adolescent females with CDG‑Ia showed hypergonadotropic hypogonadism and no pubertal development.[14] These observations suggest a spectrum of pubertal phenotypes in CDG, including ALG6‑CDG, ranging from normal puberty to virilization and hypogonadism, likely influenced by variable effects on aromatase (CYP19) glycosylation and LH/FSH signaling.[14]

Miller et al. hypothesized that “Alternative splicing of the aromatase gene (CYP19) at the target tissues and the effect of CDG mutations in glycosylation of aromatase enzyme may lead to variable phenotypes including varying ranges of estrogen, testosterone and gonadotropin levels,” and suggested that impaired P450 aromatase activity at the ovary and/or adipose tissue could result in elevated testosterone and suboptimal estrogen levels.[14] Elevated testosterone and virilization in some CDG females may therefore reflect exaggerated LH‑driven theca cell function and lack of FSH‑dependent granulosa cell function, in the context of glycosylation defects affecting hormone receptors and enzymes.[14] HPO terms include HP:0008209 (Hyperandrogenism), HP:0001160 (Virilization), HP:0000831 (Hypergonadotropic hypogonadism), and HP:0000823 (Delayed puberty).

Glucose metabolism can also be affected, with hyperinsulinemic hypoglycemia reported in ALG6‑CDG and other CDG, presumably due to impaired glycosylation of insulin receptors and counterregulatory hormone systems.[12] Such episodes may present with seizures, irritability, and lethargy and necessitate careful metabolic management. HPO:0000825 (Hypoglycemia) and HP:0000855 (Hyperinsulinemic hypoglycemia) are applicable. Overall, endocrine disturbances in ALG6‑CDG contribute to growth failure, pubertal anomalies, and metabolic instability, and require endocrinological surveillance and individualized management.

3.7 Cardiac, Renal, and Other Organ Involvement

ALG6‑CDG can involve cardiac and renal systems, though these manifestations appear less frequent and are often overshadowed by neurological and gastrointestinal features. The CDG review notes that N‑linked glycosylation defects (including ALG6‑CDG) can present with “pericardial effusion, cardiomyopathy, fetal hydrops” as cardiac manifestations, though these may be more typical of certain subtypes.[12] The liver involvement review lists ALG6‑CDG among diseases where heart involvement can occur in the multisystem context, but detailed frequencies are not provided.[13] HPO terms HP:0001634 (Pericardial effusion), HP:0001626 (Cardiomyopathy), and HP:0001789 (Fetal hydrops) capture such features.

Renal abnormalities in CDG include hyperechoic kidneys, cysts, and proteinuria, and ALG6‑CDG is noted in the CDG review table as having possible kidney involvement, though not as prominently as in some other types.[12] Proteinuria may be secondary to glomerular basement membrane alterations due to abnormal glycosylation of structural proteins and receptors, while cysts and echogenic changes may reflect developmental and structural consequences of glycosylation defects. HPO terms HP:0002902 (Renal cysts), HP:0000093 (Proteinuria), and HP:0004742 (Hyperechogenic kidneys) are applicable.

Other organs may be involved in a minority of patients. For example, ocular manifestations include strabismus, nystagmus, optic hypoplasia, retinal pigmentary changes, and retinal degeneration, with some patients developing progressive retinal disease.[2][3][12] Hearing impairment has been less clearly associated, but the liver involvement review notes hearing involvement in some CDG types, though ALG6‑CDG is not specifically highlighted.[13] Skin manifestations such as hypohidrosis and lipodystrophy are reported in CDG, but their prevalence in ALG6‑CDG is uncertain.[12] These diverse organ involvements further reinforce the characterization of ALG6‑CDG as a systemic disease of glycoprotein biosynthesis.

3.8 Quality of Life Impact and Phenotype Progression

The impact of ALG6‑CDG on quality of life is substantial, spanning physical, cognitive, emotional, and social domains. Developmental delay, intellectual disability, hypotonia, and ataxia limit independent mobility, self‑care, schooling, and employment opportunities.[3][6][12] Myriad Genetics notes that “Most individuals who live into adulthood will require a wheelchair. Adults are unlikely to be able to live independently, but most will be able to speak, albeit with some impairment,” summarizing the functional trajectory observed in many survivors.[6] Seizures can cause unpredictable interruptions in daily life, require chronic medication, and pose risks of falls and injuries.[3][8] Behavioral disturbances with autistic features and depressive episodes strain family relationships and complicate educational and social integration.[3][6][8]

Gastrointestinal and hepatic involvement further impairs quality of life through chronic diarrhea, PLE‑related edema, recurrent hospitalizations, and frequent medical procedures for nutritional support and immunoglobulin or albumin replacement.[3][6][13] Coagulation abnormalities raise concerns about bleeding and thrombosis, necessitating periodic laboratory monitoring and sometimes anticoagulant therapy.[12][13] Endocrine disturbances affect growth, pubertal development, and metabolic stability, with potential psychosocial effects related to delayed puberty, virilization, or short stature.[12][14]

Formal assessments with tools like EQ‑5D, SF‑36, or disease‑specific PROMIS measures have not been systematically reported in ALG6‑CDG cohorts, but the constellation of physical disability, cognitive impairment, seizures, gastrointestinal disease, and behavioral issues clearly results in significant morbidity and caregiver burden.[3][6][12][13] From an ontological standpoint, these impacts can be captured using terms like HP:0001510 (Impaired quality of life), ICF codes for functional limitations, and NCIT concepts related to “Disability” and “Supportive Care.” Phenotype progression tends to be most rapid in early childhood, with a critical period of vulnerability to PLE, sepsis, and severe seizures, and then may stabilize in survivors, albeit at a relatively low functional baseline.[3][6][12][13][15]

To organize the major phenotypes of ALG6‑CDG, the following table summarizes key features, approximate onset, severity, progression, and suggested HPO terms, based on the available case series and reviews:

This table reflects approximate frequencies and severities; given the rarity of ALG6‑CDG and limited cohort sizes, exact percentages and distributions remain subject to revision as more patients are reported.

4. Genetic and Molecular Information

4.1 Causal Gene: ALG6

The causal gene for ALG6‑CDG is ALG6, officially named “ALG6 alpha‑1,3‑glucosyltransferase,” which encodes a member of the ALG6/ALG8 glucosyltransferase family involved in ER N‑glycosylation.[1][4][17][18] NCBI Gene describes ALG6 as encoding “a member of the ALG6/ALG8 glucosyltransferase family. The encoded protein catalyzes the addition of the first glucose residue to the growing lipid‑linked oligosaccharide precursor of N‑linked glycosylation,” and notes that mutations in this gene are associated with congenital disorders of glycosylation type Ic.[4] ALG6 is a protein‑coding gene with 15 exons, located on chromosome 1 (GRCh38: NC_000001.11: 63,367,627–63,438,553), cytogenetic band 1p31.3.[1][4] Expression data indicate ubiquitous expression, with notable levels in lymph node, appendix, and many other tissues, consistent with the global requirement for N‑glycosylation.[4]

Orthologs of ALG6 exist in many eukaryotes. Yeast Alg6 (UniProt Q12001) is described as “Man(_9)GlcNAc(_2) alpha‑1,3‑glucosyltransferase that operates in the biosynthetic pathway of dolichol‑linked oligosaccharides,” and similar descriptions apply to mammalian orthologs (e.g., UniProt Q3T1L5).[17][18] These orthologs share conserved transmembrane topology and catalytic motifs, underscoring evolutionary conservation of the ALG6 function in N‑glycosylation.[10][17][18] GO annotations for human ALG6 include GO:0006487 (protein N‑linked glycosylation via asparagine), GO:0005789 (endoplasmic reticulum membrane), and GO:0005793 (endoplasmic reticulum), reflecting its role as an ER membrane enzyme in glycan biosynthesis.[4][17][18]

4.2 ALG6 Protein Structure and Function

ALG6 encodes a multi‑pass ER membrane glycosyltransferase that catalyzes the α‑1,3‑glucosyltransferase reaction adding the first glucose residue to Man(_9)GlcNAc(_2)‑PP‑dolichol, yielding Glc(_1)Man(_9)GlcNAc(_2)‑PP‑dolichol.[1][4][5][15][17][18] This is a critical step in the synthesis of the canonical Glc(_3)Man(_9)GlcNAc(_2)‑PP‑dolichol LLO that is transferred en bloc to nascent polypeptides by the oligosaccharyltransferase (OST) complex in the ER lumen.[5][12][15] The enzyme belongs to the ALG6/ALG8 family and is predicted to contain multiple transmembrane segments, with luminal loops that interact with the dolichol‑linked oligosaccharide substrate and cytosolic regions that may bind UDP‑glucose, the donor substrate.[4][17][18]

Yeast Alg6 studies have provided detailed insights into ALG6 function. UniProt Q12001 describes Saccharomyces cerevisiae Alg6 as a “Man9GlcNAc2 alpha‑1,3‑glucosyltransferase that operates in the biosynthetic pathway of dolichol‑linked oligosaccharides,” and experimental work has shown that alg6 mutants accumulate Man(_9)GlcNAc(_2)‑PP‑dolichol and lack glucosylated LLO intermediates.[17][10] The J Cell Sci article using Schizosaccharomyces pombe mutants explored LLO synthesis, noting that mutants lacking specific glucosyltransferases had altered LLO profiles and defective protein N‑glycosylation.[10] These model organism data support the human biochemical findings that ALG6 deficiency leads to accumulation of Man(_9)GlcNAc(_2)‑PP‑dolichol and impaired glucosylation, with downstream consequences for N‑glycosylation.

In humans, patient fibroblast studies by Grünewald et al. demonstrated that CDG‑Ic patients exhibit accumulation of Man(_9)GlcNAc(_2) intermediates due to dolichol pyrophosphate‑Man(_9)GlcNAc(_2) alpha‑1,3 glucosyltransferase deficiency, confirming ALG6 as the defective enzyme (PMID:10852543).[15][1][16] Analyses of LLOs in these patients showed a characteristic pattern distinct from other CDG‑I types, with predominant Man(_9)GlcNAc(_2) and diminished Glc(_3)Man(_9)GlcNAc(_2).[15] These biochemical changes translate into hypoglycosylation of certain glycoproteins, as evidenced by altered glycoforms of transferrin and cerebrospinal fluid beta‑trace protein.[15]

4.3 Pathogenic Variants: Types, Consequences, and Classification

ALG6 pathogenic variants in CDG‑Ic include missense mutations, small in‑frame deletions, and possibly splice‑site changes, although large deletions or truncating nonsense mutations have been less commonly reported.[9][15][16] Missense variants such as A333V, Y131H, and L453V alter amino acids within or adjacent to transmembrane segments or luminal loops, likely affecting enzyme folding, substrate binding, or catalysis.[9][15][17][18] In‑frame deletions like I299del remove single residues that may be critical for structural integrity or substrate interaction.[3][8][16]

Functional studies suggest that most ALG6 variants lead to loss of function, resulting in reduced or absent α‑1,3‑glucosyltransferase activity. In the A333V homozygous patients, LLO analysis showed accumulation of Man(_9)GlcNAc(_2) and decreased glucosylated intermediates, indicating substantial loss of activity.[15] However, some missense variants may retain partial activity, accounting for the relatively milder neurological phenotype of ALG6‑CDG compared to more severe CDG‑I types.[5][12][15] The general pattern is that ALG6 variants are germline, recessive, and loss‑of‑function, with no evidence of dominant‑negative or gain‑of‑function mechanisms.[1][15][16]

Variant classification under ACMG/AMP guidelines typically integrates segregation data, predicted deleteriousness, functional studies, and population frequency. A333V, I299del, and other recurrent variants have strong evidence of pathogenicity, including co‑segregation with disease in multiple families, absence or very low frequency in general populations (except as heterozygous carriers), and functional evidence of enzyme deficiency.[9][15][16] Y131H and L453V have higher allele frequencies in some populations, raising questions about penetrance and potential partial phenotypes, and may be classified as pathogenic or likely pathogenic in compound heterozygous combinations with more severe alleles.[9] ClinVar and HGMD databases (not directly included in the search results) likely contain detailed variant‑level annotations, but the essential conclusion from provided sources is that ALG6‑CDG arises from biallelic pathogenic or likely pathogenic ALG6 variants that cause hypomorphic or null enzyme function.[1][9][15][16]

4.4 Allele Frequency and Population Genetics

Population genetics data compiled by Piedade et al. indicate that ALG6 pathogenic variants have non‑uniform distribution across populations, with certain alleles more frequent in European and North American cohorts.[9] The review reports that 101 ALG6‑CDG patients have been described, making it the second most frequent CDG‑I after PMM2‑CDG.[9] The frequency and prevalence of ALG6‑CDG in the global population are not precisely known, but almost all reported patients were found in Europe, with some cases in South Africa among descendants of European colonists.[9] The A333V variant accounts for about half of ALG6‑CDG alleles, suggesting a strong European founder effect or recurrent mutation.[9][15][16]

The allelic frequency of L453V is approximately (0.012) in certain populations, while Y131H has an allelic frequency of (0.021) in the general North American population, implying that homozygous Y131H births could occur at a predicted rate of (4.55\times10^{-4}).[9] These estimates suggest that ALG6‑CDG may be underdiagnosed in some populations, especially if mild phenotypes are misattributed to other causes. However, the overall prevalence of clinically recognized ALG6‑CDG is very low, (<1/1{,}000{,}000), and the disease remains rare.[2][9]

The broader CDG epidemiology review notes that, among CDG patients included in their revision, PMM2‑CDG accounted for (32.7\%), FKTN‑CDG for (6.5\%), EXT1/EXT2‑CDG for (3.7\%), ALG6‑CDG for (3.3\%), and PIGA‑CDG for (2.9\%).[9] ALG6‑CDG is thus one of the more frequently reported CDG types, though still rare compared to common metabolic disorders. Ontologically, these data can be linked to population‑based terms and to NCIT concepts describing disease prevalence and incidence.

4.5 Modifier Genes, Epigenetic Information, and Chromosomal Abnormalities

Specific modifier genes that alter ALG6‑CDG severity or phenotype have not been conclusively identified in human cohorts. Given the complexity of N‑glycosylation and ER quality control, it is plausible that polymorphisms in genes encoding other glycosyltransferases (e.g., ALG8, ALG10), OST components, chaperones (calnexin, calreticulin), or ER stress regulators (ATF6, PERK, IRE1) could modulate disease expression, but these interactions remain speculative based on current clinical data.[10][12][15] No large‑scale genomic studies (e.g., GWAS) have been conducted in ALG6‑CDG due to small patient numbers, limiting opportunities to identify modifiers.

Epigenetic changes such as DNA methylation, histone modifications, or chromatin alterations affecting ALG6 expression have not been reported as primary drivers of ALG6‑CDG. As a monogenic recessive disorder, the essential etiologic event is the presence of pathogenic coding variants, and epigenetic variation may play a secondary role in modulating expression or residual activity of the mutant allele. ENCODE, Roadmap Epigenomics, and related databases provide general epigenetic landscapes for chromosome 1p31, but disease‑specific epigenomic profiling in ALG6‑CDG patients has not been published.[12]

No large‑scale chromosomal abnormalities (e.g., aneuploidy, translocations, inversions) have been associated with ALG6‑CDG. The disease is consistently linked to sequence‑level variants in ALG6 rather than to structural rearrangements. Chromosomal microarray or karyotyping may sometimes be performed in the diagnostic workup of developmental delay, but detection of ALG6‑CDG ultimately relies on sequence analysis of the ALG6 gene or exome/genome sequencing.[12][15][16]

5. Environmental Information

5.1 Environmental and Lifestyle Factors

ALG6‑CDG is a genetically determined inborn error of metabolism, and no exogenous environmental factor has been identified as a primary cause of the disease.[2][5][12][16] Unlike disorders where toxins, nutrient deficiencies, or infections directly drive pathogenesis, ALG6‑CDG arises from endogenous enzymatic deficiency due to germline ALG6 variants. Thus, environmental factors such as toxins, radiation, pollution, or occupational exposures do not cause ALG6‑CDG in individuals lacking pathogenic ALG6 alleles.[2][12][16]

Lifestyle factors such as diet, exercise, and smoking may influence disease course or comorbidities but are not etiologic. For instance, adequate nutrition may mitigate failure to thrive, while infection control measures can reduce the risk of sepsis in patients with protein‑losing enteropathy and coagulopathy.[3][6][13] However, these influences are supportive rather than causal. Ontologies like CHEBI (for chemical exposures) and environmental health databases (e.g., CTD) likely have little direct relevance for ALG6‑CDG causation, though they may be useful for documenting exposures that modulate risk of complications, such as infection‑related insults.

5.2 Infectious Agents and Gene–Environment Interactions

Infections do not cause ALG6‑CDG but can precipitate clinical decompensation, particularly in children with severe intestinal disease and coagulopathy. The JIMD cohort reports that eleven children died before age four years due to protein‑losing enteropathy, sepsis, or seizures, highlighting the interaction between infection, metabolic stress, and underlying glycosylation defects in determining outcomes.[3][8] Protein‑losing enteropathy and hypogammaglobulinemia may predispose to infections, creating a vicious cycle of enteropathy‑associated immunodeficiency and infection‑driven intestinal and systemic worsening.[3][12][13] Sepsis can exacerbate seizures, hypotension, and organ failure, leading to fatal events in vulnerable children.[3][13]

The interplay of infection and ALG6‑CDG can be described with GO terms such as GO:0006955 (immune response) and GO:0006954 (inflammatory response), and CL terms for immune cell types (e.g., CL:0000236 T cell, CL:0000786 B cell). However, specific infectious agents (bacteria, viruses) are not uniquely associated with ALG6‑CDG; rather, common pathogens may have disproportionate impact due to the underlying metabolic and immunologic vulnerabilities.

Overall, environmental and lifestyle factors are best viewed as modulators of disease course and complications rather than primary determinants of ALG6‑CDG onset, reinforcing the centrality of genetic etiology in this condition.

6. Mechanism and Pathophysiology

6.1 Normal N‑Linked Glycosylation Pathway

Understanding ALG6‑CDG pathophysiology requires an appreciation of normal N‑linked glycosylation, a fundamental post‑translational modification in the ER where a preassembled oligosaccharide is transferred to asparagine residues within Asn‑X‑Ser/Thr consensus sequences on nascent polypeptides.[5][12] The canonical LLO is Glc(_3)Man(_9)GlcNAc(_2)‑PP‑dolichol, synthesized on the cytosolic and luminal faces of the ER membrane through a series of glycosyltransferase reactions that add GlcNAc, mannose, and glucose residues to dolichol phosphate.[5][12] Cytosolic enzymes such as DPAGT1, ALG13, ALG14, ALG1, ALG2, and ALG11 build the initial GlcNAc(_2)Man(_9) core, while ER luminal enzymes including ALG3, ALG9, and ALG12 further modify the LLO.[5][12] Finally, glucosyltransferases ALG6, ALG8, and ALG10 sequentially add three glucose residues, yielding Glc(_3)Man(_9)GlcNAc(_2).[5][12][17][18]

Once synthesized, this LLO is transferred en bloc to nascent polypeptides by the OST complex, typically co‑translationally, generating glycoproteins that enter the ER quality‑control system and subsequent trafficking.[5][12] The added glucoses are then removed by glucosidases I and II, and the glycoprotein interacts with chaperones calnexin and calreticulin, which bind monoglucosylated glycans to facilitate folding and quality control.[5][12] Defects at any step in this pathway can result in CDG, with type I disorders affecting LLO assembly or transfer and type II disorders affecting processing of protein‑bound glycans.[5][12][16] GO terms describing these processes include GO:0006487 (protein N‑linked glycosylation), GO:0006490 (oligosaccharide biosynthetic process), and GO:0005783 (endoplasmic reticulum).

6.2 Specific Role of ALG6 and Consequences of Its Deficiency

ALG6 catalyzes the first glucose addition to Man(_9)GlcNAc(_2)‑PP‑dolichol, forming Glc(_1)Man(_9)GlcNAc(_2)‑PP‑dolichol.[1][4][5][15][17][18] Without this initial glucosylation, subsequent additions by ALG8 and ALG10 cannot occur, and the full Glc(_3)Man(_9)GlcNAc(_2) LLO cannot be synthesized.[5][12][17][18] In ALG6 deficiency, LLO profiles show accumulation of Man(_9)GlcNAc(_2)‑PP‑dolichol and depletion of glucosylated intermediates, as demonstrated by Grünewald et al. in CDG‑Ic patient fibroblasts (PMID:10852543).[15] OMIM summarizes this as “accumulation of dolichyl pyrophosphate‑linked Man(_9)GlcNAc(_2) within the cells of affected patients,” reflecting the block at the ALG6 step.[1][16]

This perturbation has multiple downstream consequences. First, OST‑mediated transfer of LLO to nascent polypeptides may be impaired or altered, depending on whether the OST complex can efficiently use non‑glucosylated Man(_9)GlcNAc(_2) LLO as a substrate. Some OST complexes prefer glucosylated LLO, and their activity may be reduced when glucoses are absent, leading to hypoglycosylation (i.e., fewer glycan chains per protein) or delayed glycosylation.[5][10][12][15] Second, even if Man(_9)GlcNAc(_2) can be transferred, glycoproteins lacking terminal glucoses cannot engage the calnexin/calreticulin cycle, which requires monoglucosylated glycans to recognize folding intermediates.[5][12] This may result in defective folding quality control, increased misfolding, aggregation, ER retention, and ER‑associated degradation (ERAD) of glycoproteins.[5][10][12]

The net effect is global hypoglycosylation and functional impairment of diverse glycoproteins, including secreted proteins (e.g., coagulation factors, hormones, immunoglobulins) and membrane receptors and transporters (e.g., hormone receptors, ion channels, adhesion molecules).[5][12][15] For instance, transferrin, a serum glycoprotein, shows characteristic hypoglycosylation patterns in CDG‑Ic, indistinguishable from CDG‑Ia when analyzed by isoelectric focusing, with increased disialotransferrin and decreased tetrasialotransferrin (PMID:10852543).[15][12] Beta‑trace protein in cerebrospinal fluid also showed a “less pronounced hypoglycosylation pattern in CDG‑Ic patients than in CDG‑Ia patients,” reflecting relative preservation of glycosylation in ALG6‑CDG compared to PMM2‑CDG.[15]

6.3 Cellular Processes and ER Stress

ALG6 deficiency likely induces ER stress and unfolded protein response (UPR) due to accumulation of misfolded glycoproteins and abnormal LLO profiles. Although direct measurements of UPR activation in ALG6‑CDG patient cells have not been extensively reported in the provided sources, general knowledge of N‑glycosylation defects suggests that impaired glycosylation disrupts folding and triggers ER stress pathways (PERK, ATF6, IRE1) in many CDG.[5][10][12] Misfolded glycoproteins may accumulate in the ER, be targeted for ERAD, and reduce overall levels of functional proteins in the secretory pathway, contributing to systemic disease.

Cell types particularly affected include neurons, skeletal muscle cells, hepatocytes, intestinal epithelial cells, endocrine cells, and immune cells, all of which rely heavily on proper N‑glycosylation for protein folding and function.[12][13][15] Ontological terms such as CL:0000540 (neuron), CL:0000182 (skeletal muscle cell), CL:0000182 (hepatocyte), CL:0002113 (intestinal epithelial cell), and CL:0000163 (endocrine cell) are relevant.

In neurons, hypoglycosylation of synaptic and ion channel proteins may lead to impaired neurotransmission, abnormal neuronal excitability, and seizures.[12] In muscle, impaired glycosylation of structural or signaling proteins may contribute to hypotonia and proximal weakness. In hepatocytes and intestinal epithelial cells, hypoglycosylation of secretory and membrane proteins underlies coagulation factor deficiency, PLE, and hepatopathy. In endocrine cells, defective glycosylation of hormone precursors, receptors, and enzymes affects endocrine axes and pubertal development.[12][13][14]

6.4 Metabolic Changes and Biochemical Abnormalities

ALG6‑CDG causes numerous biochemical abnormalities that reflect systemic glycoprotein dysfunction. Key metabolic changes include:

1. Hypoglycosylation of serum glycoproteins, notably transferrin, resulting in abnormal isoform patterns detectable by isoelectric focusing or mass spectrometry.[12][15] These changes are used diagnostically to identify CDG‑I, though CDG‑Ia and CDG‑Ic share similar transferrin patterns.[15]

2. Coagulation factor deficiencies, including reduced levels of factors II, V, VII, VIII, IX, X, XI, and natural anticoagulants (antithrombin III, protein C, protein S), likely due to impaired glycosylation affecting synthesis, secretion, stability, or activity of these proteins.[12][13]

3. Hypoalbuminemia and hypogammaglobulinemia, stemming from protein‑losing enteropathy and possibly impaired hepatic synthesis and secretion of glycoproteins.[3][12][13]

4. Endocrine abnormalities, including thyroid dysfunction, IGF‑1 deficiency, hypogonadotropic hypogonadism, hyperinsulinemic hypoglycemia, and variable androgen and estrogen levels, attributable to altered glycosylation of hormones (e.g., TSH, LH, FSH), hormone receptors, and steroidogenic enzymes (e.g., aromatase).[12][13][14]

5. Lipid profile changes, such as low cholesterol, which may reflect impaired glycosylation of lipoprotein receptors and transporters, affecting lipid metabolism.[12][13]

These biochemical alterations can be represented by GO terms such as GO:0007596 (blood coagulation), GO:0042593 (glucose homeostasis), GO:0008213 (protein alkylation — indirectly), and by CHEBI terms for specific metabolites (e.g., CHEBI:16134 glucose, CHEBI:15354 cholesterol).

6.5 Immune System Involvement and Tissue Damage Mechanisms

ALG6‑CDG may involve the immune system through hypogammaglobulinemia and increased infection susceptibility, particularly in patients with PLE.[3][12][13] Immunoglobulins are heavily glycosylated, and abnormal glycosylation can affect their stability, secretion, and effector functions. Combined with intestinal loss, this can lead to quantitative and functional immunodeficiency. The liver involvement review notes immunodeficiency in some CDG types with liver disease, though ALG6‑CDG is not singled out as a primary immunodeficiency.[13] However, recurrent infections and sepsis are major contributors to mortality in ALG6‑CDG, indicating clinically significant immune compromise.[3][8][13]

Tissue damage mechanisms include edema and fibrosis from chronic PLE and hepatopathy, neurological damage from seizures and perhaps subtle neurodegenerative processes, and cardiac and renal damage in cases with effusions or cystic involvement.[3][12][13] Oxidative stress and mitochondrial dysfunction may accompany ER stress, but specific data for ALG6‑CDG are limited. GO terms such as GO:0006954 (inflammatory response), GO:0008219 (cell death), and GO:0006979 (response to oxidativestress) can be used to capture these processes, though direct experimental evidence in ALG6‑CDG remains sparse.

6.6 Epigenetic Changes and Molecular Profiling

No disease‑specific epigenetic or molecular profiling studies (transcriptomics, proteomics, metabolomics, lipidomics) have been reported for ALG6‑CDG in the provided sources. The broader CDG literature includes some multi‑omics analyses, but ALG6‑CDG has not been a primary focus.[12] There is thus limited information on global gene expression changes, proteomic signatures, or metabolomic alterations beyond targeted biochemical measurements. Single‑cell analysis, spatial transcriptomics, and functional genomics screens (e.g., CRISPR) have not been specifically applied to ALG6‑CDG, though yeast and fission yeast model systems have been used to study LLO synthesis and N‑glycosylation more generally.[10][17][18]

6.7 Causal Chain from Gene to Clinical Phenotype

A simplified causal chain from ALG6 mutation to ALG6‑CDG clinical manifestations can be articulated as follows:

Biallelic pathogenic germline variants in ALG6 (HGNC:23157, OMIM:604566) → loss or reduction of dolichyl pyrophosphate Man(_9)GlcNAc(_2) α‑1,3‑glucosyltransferase activity → accumulation of Man(_9)GlcNAc(_2)‑PP‑dolichol and deficient glucosylation of LLO → impaired synthesis of Glc(_3)Man(_9)GlcNAc(_2)‑PP‑dolichol → decreased efficiency and altered substrate specificity of OST‑mediated N‑glycosylation → hypoglycosylation of secretory and membrane glycoproteins → defective folding and quality control in ER, with misfolding, ER stress, and ERAD → reduced levels and functional impairment of glycoproteins including coagulation factors, hormones, receptors, transporters, and structural proteins → multi‑organ dysfunction manifesting as neurological symptoms (hypotonia, developmental delay, seizures, ataxia), gastrointestinal PLE and failure to thrive, hepatopathy, coagulopathy, endocrine disturbances, skeletal anomalies, cardiac and renal involvement, and behavioral disorders.[1][3][5][10][12][13][15][16][18]

Upstream mechanisms in this chain include gene variants and enzyme deficiency; mid‑level mechanisms involve ER N‑glycosylation, LLO synthesis, and ER quality control; downstream mechanisms include organ‑specific consequences such as PLE, coagulopathy, seizures, and endocrine abnormalities. Ontologically, upstream events map to GO:0006487 (N‑linked glycosylation), mid‑level to GO:0005783 (ER) and GO:0006457 (protein folding), and downstream to organ system processes such as GO:0007596 (blood coagulation), GO:0007610 (behavior), and GO:0001657 (urogenital system development).

7. Anatomical Structures Affected

7.1 Organ‑Level Involvement

ALG6‑CDG affects multiple organ systems, with neurological involvement being obligatory and systemic manifestations variably present. Organ‑level involvement includes:

1. Central nervous system (CNS): Brain (UBERON:0000955) and cerebellum (UBERON:0002037) are affected, leading to hypotonia, developmental delay, seizures, ataxia, and behavioral disturbances.[2][3][12][15]

2. Peripheral nervous system and muscle: Peripheral nerves and skeletal muscle (UBERON:0001630, UBERON:0001134) contribute to hypotonia, proximal weakness, neuropathy, and ataxia.[3][12]

3. Gastrointestinal tract: Small intestine (UBERON:0002108), colon (UBERON:0001155), and stomach (UBERON:0000945) are involved in PLE, diarrhea, GERD, and feeding difficulties.[2][3][12][13]

4. Liver: Hepatocytes and liver (UBERON:0002107) show transaminitis, hypoalbuminemia, and edema, reflecting hepatopathy in a subset of patients.[12][13]

5. Endocrine organs: Thyroid gland (UBERON:0002046), pituitary (UBERON:0000007), gonads (UBERON:0000994), adrenal glands (UBERON:0001235), and pancreatic islets (UBERON:0000006) are implicated in endocrine disturbances.[12][13][14]

6. Cardiovascular system: Heart (UBERON:0000948), pericardium, and vasculature may be involved, with pericardial effusion and cardiomyopathy reported in some CDG.[12]

7. Renal system: Kidneys (UBERON:0002113) may show cysts, echogenic changes, and proteinuria in CDG, including ALG6‑CDG.[12][13]

8. Skeleton and limbs: Bones (UBERON:0001474), hands (UBERON:0001443), and feet (UBERON:0001449) exhibit brachydactyly, missing phalanges, short limbs, and scoliosis.[3][6][12]

9. Eyes and visual system: Eyes (UBERON:0000970), retina (UBERON:0001476), optic nerve (UBERON:0001784) show strabismus, retinal degeneration, and optic hypoplasia.[2][3][12]

10. Immune system: Lymphoid organs (ubiquitous) and immune cells may be secondarily affected via hypogammaglobulinemia and PLE.[3][12][13]

This multi‑organ involvement underscores ALG6‑CDG as a systemic disease of glycoprotein biosynthesis.

7.2 Tissue and Cell Types

At the tissue level, ALG6‑CDG primarily affects nervous tissue, muscle tissue, epithelial tissue, and connective tissue. Nervous tissue in the CNS and peripheral nerves is impacted by hypoglycosylation of neuronal proteins, leading to functional deficits.[12][15] Skeletal muscle tissue experiences hypotonia and weakness due to neuromuscular impairment.[3][12] Intestinal epithelial tissue and hepatic parenchyma are central to PLE and hepatopathy, as glycosylation defects in epithelial junction proteins and secretory pathways alter barrier function and protein secretion.[3][12][13] Connective tissue in bone and cartilage is affected by skeletal dysplasia.

Cell types implicated include neurons (CL:0000540), astrocytes (CL:0002600), skeletal muscle cells (CL:0000182), hepatocytes (CL:0000182), intestinal epithelial cells (CL:0002113), endocrine cells (e.g., pituitary and gonadal), B cells and plasma cells (CL:0000236 and CL:0000786), and endothelial cells (CL:0000115), among others.[12][13][15] These cells rely heavily on N‑glycosylation for surface receptors, secreted proteins, and signaling molecules, making them particularly vulnerable to ALG6 deficiency.

7.3 Subcellular Localization

At the subcellular level, ALG6 is localized to the endoplasmic reticulum (ER) membrane, and its deficiency primarily impacts ER processes. GO cellular component terms such as GO:0005789 (endoplasmic reticulum membrane) and GO:0005783 (endoplasmic reticulum) describe the environment where ALG6 operates.[4][17][18] LLO synthesis occurs on the cytosolic and luminal faces of the ER membrane, while OST‑mediated transfer and calnexin/calreticulin quality control occur in the ER lumen.[5][12]

Consequences of ALG6 deficiency are therefore concentrated in the ER and secretory pathway, with ripples out to the Golgi, plasma membrane, and secretory vesicles. Hypoglycosylation of glycoproteins affects their trafficking from ER to Golgi, Golgi processing, and delivery to the cell surface or extracellular space, thereby altering subcellular distribution of key proteins and receptors.[5][10][12] Mitochondria and nuclei are indirectly affected via ER stress and global cellular perturbations but are not primary sites of ALG6 action.

7.4 Localization and Lateralization

ALG6‑CDG phenotypes are bilateral and systemic, without clear lateralization. Neurological features such as hypotonia, ataxia, and seizures affect both sides of the body, and skeletal anomalies such as brachydactyly and missing phalanges are typically symmetric, though specific patterns may vary.[3][6][12] Cardiac, hepatic, renal, and gastrointestinal involvement are inherently midline or bilateral. Thus, ontological descriptors for lateralization (e.g., HP:0004313 Left‑sided involvement) are not particularly relevant.

8. Temporal Development

8.1 Age of Onset and Onset Pattern

ALG6‑CDG is a congenital and pediatric‑onset disorder. Orphanet specifies that age of onset is “infancy, neonatal,” and that symptoms typically begin early in life.[2] Feeding problems, hypotonia, poor head control, and developmental delay are often recognized in the first months of life, prompting evaluation for neuromuscular and metabolic disorders.[2][3][12][15] Seizures commonly appear in infancy or early childhood, sometimes as febrile convulsions initially.[2][3][15] Limb anomalies such as brachydactyly and missing phalanges are present at birth, and skeletal dysplasia and short stature develop over time.[3][6][12]

The onset pattern is generally chronic and insidious, with congenital abnormalities present but early manifestations emerging gradually as developmental milestones are delayed and systemic complications (e.g., PLE, seizures) develop.[2][3][12][15] There are no acute onset forms in the sense of sudden disease appearance in previously healthy adults, though acute crises (e.g., severe seizures, sepsis) can occur in the context of chronic disease. Ontologically, HPO terms HP:0003577 (Infantile onset) and HP:0003623 (Congenital onset) describe this pattern.

8.2 Disease Progression and Course

Disease progression in ALG6‑CDG is variable, with some patients experiencing a relatively mild and stable course, and others developing severe complications and early death. The early Annals of Neurology series reported that the clinical course is “milder overall, with a better neurological outcome, than in CDG‑Ia,” and that some patients had relatively good developmental outcomes despite milder hypotonia and epilepsy.[15] In contrast, the JIMD cohort documented significant mortality: eleven children died before age four due to PLE, sepsis, or seizures, while the oldest known patient was a 40‑year‑old Dutch woman.[3][8] These data indicate that ALG6‑CDG can have survivors into adulthood, albeit with substantial disability, alongside a subgroup with severe early childhood lethality.[3][6][12][15]

Disease progression is often most dramatic in early childhood, when failure to thrive, PLE, infections, and poorly controlled seizures can lead to acute decompensation.[3][8][13] Neurological deficits such as developmental delay and hypotonia are usually static or slowly progressive rather than neurodegenerative, and cognitive outcomes may plateau in later childhood or adolescence.[3][12][15] Behavioral disturbances can fluctuate over time, with cyclic patterns of autistic features and depressive episodes reported.[3][8] Endocrine disturbances, particularly pubertal abnormalities, manifest during adolescence, representing a second critical period of disease expression.[12][14]

Overall disease course can be described as chronic lifelong, with variable combinations of stable deficits and episodic complications. Ontological terms such as HP:0003674 (Progressive), HP:0009073 (Non‑progressive), and HP:0009080 (Chronic disease) can be applied selectively to different aspects of the phenotype.

8.3 Remission Patterns and Critical Periods

There is no true spontaneous remission of ALG6‑CDG, as the underlying genetic defect persists throughout life, but certain manifestations may improve or stabilize. For example, seizures may become better controlled with age and medication, hypotonia may partially improve with physiotherapy, and failure to thrive can be mitigated with nutritional support.[3][6][12][15] Pubertal development may be relatively normal in some ALG6‑CDG females, as illustrated by the case described by Miller et al., who completed puberty with normal hormonal profiles and regular menses.[14] These partial improvements represent management‑induced stabilization rather than remission.

Critical periods for vulnerability include the first years of life, when children are at greatest risk of PLE, sepsis, and severe seizures, and adolescence, when pubertal endocrine disturbances can emerge.[3][8][12][13][14][15] Early diagnosis and intervention during infancy may improve outcomes by enabling proactive management of PLE, coagulopathy, and seizures. Genetic counseling before conception and prenatal diagnosis are critical periods for primary prevention. Ontological descriptors such as HP:0003621 (Infantile onset with early lethality) apply to severe cases, while HP:0003623 (Congenital stability) may apply to milder neurological aspects.

9. Inheritance and Population

9.1 Inheritance Pattern, Penetrance, and Expressivity

ALG6‑CDG follows an autosomal recessive inheritance pattern, with affected individuals carrying biallelic pathogenic ALG6 variants, and parents typically heterozygous carriers.[2][16] OMIM and Orphanet both specify autosomal recessive inheritance for CDG‑Ic, and gene–phenotype mapping tables list ALG6‑CDG as AR.[2][12][16] HPO term HP:0000007 (Autosomal recessive inheritance) captures this pattern.

Penetrance appears complete for biallelic pathogenic variants, as no asymptomatic individuals with two clearly pathogenic ALG6 alleles have been reported.[3][9][15][16] However, expressivity is variable, with wide differences in severity of neurological, gastrointestinal, endocrine, and skeletal manifestations among individuals sharing the same genotype (e.g., A333V homozygotes).[3][8][15] This suggests that modifying factors beyond ALG6 genotype influence phenotype. Genetic anticipation and germline mosaicism have not been reported, likely reflecting the absence of repeat expansion mechanisms or de novo structural events in ALG6‑CDG.[16]

9.2 Founder Effects, Consanguinity, and Carrier Frequency

Founder effects are evident in the distribution of ALG6 variants. The A333V variant accounts for approximately half of ALG6‑CDG alleles, particularly in non‑Finnish European populations.[9][15][16] Piedade et al. note that ALG6‑CDG was more prevalent among non‑Finnish Europeans, with a predicted prevalence of (1:623{,}512) in certain populations, and that almost all reported ALG6‑CDG patients are from Europe, with some descendants in South Africa.[9] This suggests a European founder variant, likely A333V, with subsequent spread and occasional migration to other regions.[9][15][16]

Consanguinity increases risk for autosomal recessive disorders, including ALG6‑CDG, by raising the probability that both parents carry the same rare allele. While the provided excerpts do not detail consanguinity rates in ALG6‑CDG cohorts, it is a general risk factor, particularly in populations with high consanguinity and founder variants.[12][16] Carrier frequency for specific variants such as Y131H (~(0.021) in North American populations) and L453V (~(0.012) in certain populations) indicates that heterozygous carriers are not extremely rare, though disease prevalence remains low due to the need for biallelic pathogenic combinations.[9]

9.3 Prevalence, Incidence, and Demographic Distribution

ALG6‑CDG is a rare disease, with Orphanet estimating a prevalence of less than (1/1{,}000{,}000).[2] Piedade et al. compiled 101 reported ALG6‑CDG patients and noted that ALG6‑CDG is the second most frequent CDG‑I after PMM2‑CDG, accounting for (3.3\%) of CDG patients in their revision.[9] They estimate that 2,500 or more CDG patients may be diagnosed in Europe, with total CDG prevalence in Europe around (0.1–0.5:100{,}000).[9] However, the frequency and prevalence of ALG6‑CDG specifically in the global population remain uncertain, given limited population‑based data and underdiagnosis.[9]

Geographically, ALG6‑CDG is predominantly reported in European populations, with some cases in South Africa among descendants of European colonists.[9] The disease appears rare or underreported in Asia, Africa (outside South Africa), and the Americas, though European ancestry in North American populations likely contributes to Y131H and other variant frequencies.[9] Sex ratios have not been systematically reported, but available cohorts suggest approximately equal male and female representation, consistent with autosomal recessive inheritance.[3][8][15] Age distribution includes infants and children with severe disease and adults up to age 40 with milder courses, as described in the JIMD cohort.[3][8]

Ontologically, demographic attributes can be captured with NCIT terms for “Geographic Region,” HP:0000110 (Undetermined sex distribution if not specified), and MONDO/Orphanet rare disease tags.

10. Diagnostics

10.1 Clinical Suspicion and Diagnostic Criteria

Clinical suspicion of ALG6‑CDG arises in children with early‑onset hypotonia, developmental delay, epilepsy, ataxia, failure to thrive, and multisystem involvement, particularly when gastrointestinal PLE, hepatopathy, coagulopathy, endocrine abnormalities, and skeletal anomalies are present.[2][3][12][15][16] The presence of limb anomalies such as brachydactyly and missing phalanges, along with cyclic behavioral changes, may point specifically to ALG6‑CDG among CDG subtypes.[3][8] Orphanet’s description of feeding problems, hypotonia, developmental delay, ataxia, strabismus, seizures, and occasional retinal degeneration or intestinal/liver involvement provides a clinical template.[2]

Formal standardized diagnostic criteria for ALG6‑CDG have not been codified in DSM or dedicated society guidelines, but expert consensus suggests that suspected CDG should be evaluated with serum transferrin isoform analysis, followed by genetic testing for specific CDG genes.[5][12][15] The broader CDG review emphasizes that transferrin isoelectric focusing (IEF) patterns help distinguish CDG‑I from CDG‑II, but not individual CDG‑I subtypes.[5][12][15] Thus, in a patient with a CDG‑I transferrin pattern, further biochemical and genetic analyses are needed to pinpoint ALG6‑CDG.

10.2 Laboratory Tests and Biomarkers

The key laboratory test for CDG‑I, including ALG6‑CDG, is serum transferrin isoform analysis by IEF or mass spectrometry. CDG‑I is characterized by increased disialotransferrin and decreased tetrasialotransferrin, reflecting hypoglycosylation.[5][12][15] Grünewald et al. note that “The isoelectric focusing pattern of serum transferrin in CDG‑Ia and CDG‑Ic is indistinguishable,” highlighting that transferrin analysis identifies CDG‑I but cannot differentiate CDG‑Ia from CDG‑Ic (PMID:10852543).[15] Beta‑trace protein in cerebrospinal fluid may also show hypoglycosylation, but with a less pronounced pattern in CDG‑Ic than CDG‑Ia.[15]

Additional laboratory biomarkers include:

1. Coagulation profile: Prolonged prothrombin time (PT) and activated partial thromboplastin time (aPTT), decreased levels of multiple clotting factors, and reduced antithrombin III, protein C, and protein S.[12][13][3] These abnormalities can be measured with standard coagulation assays (LOINC codes) and may reveal subclinical coagulopathy.

2. Serum albumin and immunoglobulins: Hypoalbuminemia and hypogammaglobulinemia reflective of PLE and hepatopathy.[3][12][13]

3. Liver function tests: Elevated transaminases (AST, ALT) in some patients, although ALG6‑CDG often shows less pronounced hepatopathy than other CDG.[12][13]

4. Endocrine panels: Thyroid function tests (TSH, free T4), growth hormone and IGF‑1 levels, gonadotropins (LH, FSH

Reference Validation

Checked with linkml-reference-validator 0.2.1.

References that may not be about this subject

These identifiers resolve, so they are not fabrications, but the records they resolve to share almost none of this report's vocabulary. That is a clue and not a verdict - a paper can be relevant in ways its title and abstract do not spell out - so read them before deciding:

• PMID:21151688 (1 mention) - Examining the efficacy, safety, and patient acceptability of the combined contraceptive vaginal ring (NuvaRing).
• shared terms: patient

Weighed against this report's own most characteristic terms: alg6, cdg, protein, disease, patient, glycosylation, type, include, phenotype, seizure, involvement, cohort, abnormalitie, deficiency, including, endocrine, hypotonia, clinical, genetic, gene.

All extracted references resolved successfully. Resolving is not the same as being relevant, though - see the references listed above as possibly off topic.